The impact of a medical food containing gammalinolenic and eicosapentaenoic acids on asthma management and the quality of life of adult asthma patients

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 559-567

  Surette, Marc E ^a   Stull, Dean ^b   Lindemann, Julianne ^b  

^a UNIVERSITÉ DE MONCTON   (Canada)

^b Efficas Inc   (United States)

Author keywords

Asthma; Dietary fatty acids; Leukotriene; Quality of life

Indexed keywords

BRONCHODILATING AGENT; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; PLACEBO;

ADULT; ANALYTICAL ERROR; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG UTILIZATION; FEMALE; FOOD INTAKE; HUMAN; MALE; OPEN STUDY; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; STATISTICAL SIGNIFICANCE;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; EICOSAPENTAENOIC ACID; FEMALE; FOOD, FORTIFIED; GAMMA-LINOLENIC ACID; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MALE; NUTRITIONAL STATUS; QUALITY OF LIFE; QUESTIONNAIRES; RESPIRATORY FUNCTION TESTS; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

EID: 39749177714     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X273011     Document Type: Article

References (40)

1. Smith MJ, Ford-Hutchinson AW, Bray MA. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol 1980;32:517-18
2. Piper PJ, Samhoun MN, Tippins JR, et al. Slow-reacting substances and their formation by a lipoxygenase pathway. Agents Actions 1980;10:541-7
3. Goetzl EJ. Leukocyte recognition and metabolism of leukotrienes. Fed Proc 1983;42:3128-31
4. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52
5. Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996;97:646-54
6. Wenzel SE, Trudeau JB, Kaminsky DA, et al. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Respir Crit Care Med 1995;152:897-905
7. Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006;13:3213-26
8. Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006;38:493-502
9. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 2007;67:887-901
10. Poff CD, Balazy M. Drugs that target lipoxygenases and leukotrienes as emerging therapies for asthma and cancer. Curr Drug Targets Inflamm Allergy 2004;3:19-33
11. Leonardi S, Marchese G, Marseglia GL, La Rosa M. Montelukast in allergic diseases beyond asthma. Allergy Asthma Proc. 2007;28:287-91
12. Chilton-Lopez T, Surette ME, Swan DD, et al. Metabolism of gammalinolenic acid in human neutrophils. J Immunol 1996;156:2941-7
13. Chapkin RS, Miller CC, Somers SD, Erickson KL. Utilization of dihomo-gamma-linolenic acid (8,11,14-eicosatrienoic acid) by murine peritoneal macrophages. Biochim Biophys Acta 1988;959:322-31
14. Johnson MM, Swan DD, Surette ME, et al. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr 1997;127:1435-44
15. Pullman-Mooar S, Laposata M, Lem D, et al. Alteration of the cellular fatty acid profile and the production of eicosanoids in human monocytes by gamma-linolenic acid. Arthritis Rheum 1990;33:1526-33
16. Ziboh VA, Fletcher MP. Dose-response effects of dietary gamma-linolenic acid-enriched oils on human polymorphonuclear-neutrophil biosynthesis of leukotriene B4. Am J Clin Nutr 1992;55:39-45
17. Barham JB, Edens MB, Fonteh AN, et al. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr 2000;130:1925-31
18. Surette ME, Koumenis IL, Edens MB, et al. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clin Ther 2003;25:948-71
19. Surette ME, Koumenis IL, Edens MB, et al. Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial. Clin Ther 2003;25:972-9
20. Pacheco Y, Hosni R, Chabannes B, et al. Leukotriene B4 level in stimulated blood neutrophils and alveolar macrophages from healthy and asthmatic subjects. Effect of beta-2 agonist therapy. Eur J Clin Invest 1992;22:732-9
21. Radeau T, Chavis C, Damon M, et al. Enhanced arachidonic acid metabolism and human neutrophil migration in asthma. Prostaglandins Leukot Essent Fatty Acids 1990;41:131-8
22. Shindo K, Koide K, Fukumura M. Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor. Thorax 1997;52:1024-9
23. Cheria-Sammari S, Aloui R, Gormand F, et al. Leukotriene B4 production by blood neutrophils in allergic rhinitis - effects of cetirizine. Clin Exp Allergy 1995;25:729-36
24. Sampson AP, Thomas RU, Costello JF, Piper PJ. Enhanced leukotriene synthesis in leukocytes of atopic and asthmatic subjects. Br J Clin Pharmacol 1992;33:423-30
25. Orphan Drug Amendments of 1988. United States Public law 97-414
26. Food and Drug Administration. Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. US. Department of Health and Human Services. http://www.fda.gov/CDER/GUIDANCE/ 5460dft.pdf. 2006
27. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7
28. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-8
29. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7
30. Pinnock H, Juniper EF, Sheikh A. Concordance between supervised and postal administration of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) and Asthma Control Questionnaire (ACQ) was very high. J Clin Epidemiol 2005;58:809-14
31. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005;99:553-8. Epub 2004, Nov 26
32. Juniper EF, O'Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respir Med 2001;95:319-23
33. Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. Am J Resp Crit Care Med 2001;163:924-9
34. Ehrs PO, Nokela M, Stallberg B, et al. Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest 2006;129:925-32
35. Riccioni G, Della Vecchia R, et al. Effect of the two different leukotriene receptor antagonists, montelukast and zafirlukast, on quality of life: a 12-week randomized study. Allergy Asthma Proc 2004;25:445-8
36. Juniper EF, Stahl E, O'Byrne PM. Minimal important difference for the asthma control questionnaire. Am J Respir Crit Care Med 2001;163:A642
37. Pinnock H, Sheikh A, Juniper EF. Evaluation of an intervention to improve successful completion of the Mini-AQLQ: comparison of postal and supervised completion. Prim Care Respir J 2004;13:36-41
38. Baghi H, Atherton M. Construct validity and reliability of scores on scales to measure the impairment of health-related quality of life in persons with asthma. J Nurs Meas 2004;12:21-31
39. Wenzel SE. The role of leukotrienes in asthma. Prostaglandins Leukot Essent Fatty Acids 2003;69:145-55
40. Creticos PS. Treatment options for initial maintenance therapy of persistent asthma: a review of inhaled corticosteroids and leukotriene receptor antagonists. Drugs 2003;63:1-20